National Bank of Canada
NBIX icon

National Bank of Canada’s Neurocrine Biosciences NBIX Stock Holding History

National Bank of Canada’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-452
Closed -$50K – 3154
2025
Q1 		$50K Sell
452
-5
-1% -$633 ﹤0.01% 1884
2024
Q4 		$62.5K Sell
457
-894
-66% -$111K ﹤0.01% 1875
2024
Q3 		$156K Buy
1,351
+614
+83% +$84.2K ﹤0.01% 1438
2024
Q2 		$103K Buy
737
+15
+2% +$2.06K ﹤0.01% 1475
2024
Q1 		$98.7K Sell
722
-22,244
-97% -$3.04M ﹤0.01% 1554
2023
Q4 		$3.03M Buy
22,966
+21,964
+2,192% +$2.53M ﹤0.01% 913
2023
Q3 		$111K Sell
1,002
-52
-5% -$5.48K ﹤0.01% 1604
2023
Q2 		$99.3K Sell
1,054
-65,673
-98% -$6.42M ﹤0.01% 1594
2023
Q1 		$6.75M Buy
66,727
+55,598
+500% +$5.79M 0.02% 521
2022
Q4 		$1.33M Buy
11,129
+9,985
+873% +$1.17M ﹤0.01% 994
2022
Q3 		$129K Sell
1,144
-150
-12% -$15.2K ﹤0.01% 1468
2022
Q2 		$126K Buy
1,294
+31
+2% +$2.86K ﹤0.01% 1512
2022
Q1 		$118K Buy
1,263
+34
+3% +$2.88K ﹤0.01% 1620
2021
Q4 		$105K Buy
+1,229
New +$113K ﹤0.01% 1619

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

National Bank of Canada's NBIX Position: Q2 2025 in Review

National Bank of Canada sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 452 shares — an estimated $50K sold.

National Bank of Canada first reported a position in NBIX in Q4 2021 and held it in 14 quarters. The position peaked at $6.75M in Q1 2023. 586 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • National Bank of Canada reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
  • National Bank of Canada sold 452 Neurocrine Biosciences shares in Q2 2025, an estimated $50K.
  • National Bank of Canada first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 14 quarters.
  • National Bank of Canada's Neurocrine Biosciences position peaked at $6.75M in Q1 2023.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on National Bank of Canada's 13F filing for Q2 2025, filed 13 Aug 2025.